In today’s recent session, 6.54 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have been traded, and its beta is 0.83. Most recently the company’s share price was $6.89, and it changed around -$0.5 or -6.83% from the last close, which brings the market valuation of the company to $2.60B. RXRX at last check was trading at a discount to its 52-week high of $15.74, offering almost -128.45% off that amount. The share price’s 52-week low was $5.60, which indicates that the recent value has risen by an impressive 18.72% since then. We note from Recursion Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 16.59 million shares, with the 3-month average coming to 9.91 million.
Recursion Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.43. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 6 recommended RXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Recursion Pharmaceuticals Inc is expected to report earnings per share of -0.41 for the current quarter.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has been showing red trend so far today with a performance of -6.83% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 7.86 on recent trading dayincreased the stock’s daily price by 12.34%. The company’s shares are currently down -30.17% year-to-date, but still up 14.18% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 7.92% up in the 30-day period. We can see from the shorts that 67.1 million shares have been sold at a short interest cover period of 4.72 day(s).
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 37.36% from its current value. Analyst projections state that RXRX is forecast to be at a low of $6 and a high of $12.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Recursion Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -7.71 percent over the past six months and at a 0.63% annual growth rate that is well below the industry average of 16.60%. The year-over-year growth rate is expected to be 57.04%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 18.17M in revenue for the current quarter. 4 analysts expect Recursion Pharmaceuticals Inc to make 12.97M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 10.89M and 13.79M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 66.85%. Forecasts for the next quarter put sales growth at -5.94%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.41%. Recursion Pharmaceuticals Inc earnings are expected to increase by 2.45% in 2024, but the outlook is positive 12.00% per year for the next five years.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in January.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 3.53% of Recursion Pharmaceuticals Inc shares, and 69.03% of them are in the hands of institutional investors. The stock currently has a share float of 71.56%. Recursion Pharmaceuticals Inc stock is held by 355.0 institutions, with ARK INVESTMENT MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 11.924% of the shares, which is about 28.14 million shares worth $211.07 million.
BAILLIE GIFFORD & CO, with 11.266% or 26.59 million shares worth $199.42 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
